1
|
Osman K, Mundodan J, Chowdhury J, Ravi R, Baaboura R, Albuquerque J, Riaz B, Emran RY, Batoul K, Esameldin AM, Al Tabatabaee Z, Khogali H, Albayat S. Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12-17 Years against COVID-19 Infection in Qatar. Vaccines (Basel) 2023; 11:1522. [PMID: 37896926 PMCID: PMC10610824 DOI: 10.3390/vaccines11101522] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 09/03/2023] [Accepted: 09/18/2023] [Indexed: 10/29/2023] Open
Abstract
Qatar was also hit hard by the global pandemic of SARS-CoV-2, with the original virus, Alpha variant, Beta variant, Omicron BA.1 and BA.2 variants, Omicron BA.4 and BA.5 variants, and Delta variant, sequentially. The two-dose primary series of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine against SARS-CoV-2 infection has been approved for use in 30 µg formulations among children and adolescents aged 12-17 years as of 16 May 2021. This study aimed at estimating the effectiveness of the 30 µg BNT162b2 Pfizer-BioNTech mRNA COVID-19 vaccine against the pre-Omicron variants of SARS-CoV-2 infection in children and adolescents aged 12-17 years residing in Qatar. A test-negative matched case-control study was conducted. The subjects included any child or adolescent aged 12-17 years who had been tested for SARS-CoV-2 using RT-PCR tests performed on nasopharyngeal or oropharyngeal swabs, as part of contact tracing, between June and November 2021, and was eligible to receive the BNT162b2 vaccine as per the national guidelines. Data regarding 14,161 children/adolescents meeting inclusion-exclusion criteria were retrieved from the national Surveillance and Vaccine Electronic System (SAVES). Of the total, 3.1% (444) were positive for SARS-CoV-2. More than half (55.96%) were vaccinated with two doses of Pfizer-BioNTech-mRNA COVID-19 vaccine. Amongst those immunized with two doses, 1.2% tested positive for SARS-CoV-2, while 5.6% amongst the unvaccinated tested positive. The vaccine effectiveness was calculated to be 79%. Pfizer-BioNTech mRNA COVID-19 vaccine provides protection from COVID-19 infection for children/adolescents; hence, it is crucial to ensure they receive the recommended vaccines.
Collapse
Affiliation(s)
- Khadieja Osman
- National COVID-19 Track & Trace Team, Ministry of Public Health, Doha P.O. Box 42, Qatar; (K.O.); (J.C.); (R.R.); (R.B.); (J.A.); (B.R.); (R.Y.E.); (H.K.); (S.A.)
| | - Jesha Mundodan
- National COVID-19 Track & Trace Team, Ministry of Public Health, Doha P.O. Box 42, Qatar; (K.O.); (J.C.); (R.R.); (R.B.); (J.A.); (B.R.); (R.Y.E.); (H.K.); (S.A.)
- Vaccination Section, Ministry of Public Health, Doha P.O. Box 42, Qatar
| | - Juel Chowdhury
- National COVID-19 Track & Trace Team, Ministry of Public Health, Doha P.O. Box 42, Qatar; (K.O.); (J.C.); (R.R.); (R.B.); (J.A.); (B.R.); (R.Y.E.); (H.K.); (S.A.)
- Vaccination Section, Ministry of Public Health, Doha P.O. Box 42, Qatar
| | - Rejoice Ravi
- National COVID-19 Track & Trace Team, Ministry of Public Health, Doha P.O. Box 42, Qatar; (K.O.); (J.C.); (R.R.); (R.B.); (J.A.); (B.R.); (R.Y.E.); (H.K.); (S.A.)
- Vaccination Section, Ministry of Public Health, Doha P.O. Box 42, Qatar
| | - Rekayahouda Baaboura
- National COVID-19 Track & Trace Team, Ministry of Public Health, Doha P.O. Box 42, Qatar; (K.O.); (J.C.); (R.R.); (R.B.); (J.A.); (B.R.); (R.Y.E.); (H.K.); (S.A.)
- Vaccination Section, Ministry of Public Health, Doha P.O. Box 42, Qatar
| | - Jeevan Albuquerque
- National COVID-19 Track & Trace Team, Ministry of Public Health, Doha P.O. Box 42, Qatar; (K.O.); (J.C.); (R.R.); (R.B.); (J.A.); (B.R.); (R.Y.E.); (H.K.); (S.A.)
- Vaccination Section, Ministry of Public Health, Doha P.O. Box 42, Qatar
| | - Bilal Riaz
- National COVID-19 Track & Trace Team, Ministry of Public Health, Doha P.O. Box 42, Qatar; (K.O.); (J.C.); (R.R.); (R.B.); (J.A.); (B.R.); (R.Y.E.); (H.K.); (S.A.)
- Vaccination Section, Ministry of Public Health, Doha P.O. Box 42, Qatar
| | - Reem Yusuf Emran
- National COVID-19 Track & Trace Team, Ministry of Public Health, Doha P.O. Box 42, Qatar; (K.O.); (J.C.); (R.R.); (R.B.); (J.A.); (B.R.); (R.Y.E.); (H.K.); (S.A.)
- Vaccination Section, Ministry of Public Health, Doha P.O. Box 42, Qatar
| | - Khatija Batoul
- National COVID-19 Track & Trace Team, Ministry of Public Health, Doha P.O. Box 42, Qatar; (K.O.); (J.C.); (R.R.); (R.B.); (J.A.); (B.R.); (R.Y.E.); (H.K.); (S.A.)
| | - Abdul Mahmood Esameldin
- National COVID-19 Track & Trace Team, Ministry of Public Health, Doha P.O. Box 42, Qatar; (K.O.); (J.C.); (R.R.); (R.B.); (J.A.); (B.R.); (R.Y.E.); (H.K.); (S.A.)
| | - Zinah Al Tabatabaee
- National COVID-19 Track & Trace Team, Ministry of Public Health, Doha P.O. Box 42, Qatar; (K.O.); (J.C.); (R.R.); (R.B.); (J.A.); (B.R.); (R.Y.E.); (H.K.); (S.A.)
| | - Hayat Khogali
- National COVID-19 Track & Trace Team, Ministry of Public Health, Doha P.O. Box 42, Qatar; (K.O.); (J.C.); (R.R.); (R.B.); (J.A.); (B.R.); (R.Y.E.); (H.K.); (S.A.)
- Vaccination Section, Ministry of Public Health, Doha P.O. Box 42, Qatar
| | - Soha Albayat
- National COVID-19 Track & Trace Team, Ministry of Public Health, Doha P.O. Box 42, Qatar; (K.O.); (J.C.); (R.R.); (R.B.); (J.A.); (B.R.); (R.Y.E.); (H.K.); (S.A.)
- Vaccination Section, Ministry of Public Health, Doha P.O. Box 42, Qatar
| |
Collapse
|
2
|
Günes Ö, Gülhan B, Guney AY, Üçkardeş F, Ozen S, Guder L, Mustafaoglu O, Bayraktar P, Yahşi A, Erat T, Kanik-Yuksek S, Bayhan GI, Ozkaya-Parlakay A. Do parents vaccinated against COVID-19 protect their children from hospitalization due to COVID-19? J Trop Pediatr 2022; 69:6957047. [PMID: 36548396 DOI: 10.1093/tropej/fmac105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
OBJECTIVE This study aimed to determine whether parental vaccination against coronavirus disease 2019 (COVID-19) prevents hospitalization of COVID-19-infected children. METHODS This study was based on data obtained from the records of pediatric patients that were followed up for virologically proven COVID-19 infection between August and October 2021, during which time the delta variant was dominant in Turkey and the children were isolating at home. RESULTS There were 151 patients in the inpatient group and 218 in the outpatient group; the mean age was 172.5 and 145.5 months in the groups, respectively. The rates of obesity (22.5% and 6.4%, respectively, p < 0.001) and neurological-neurodevelopmental disorders (8.6% and 1.4%, respectively, p < 0.001) were significantly higher in the inpatient group than in the outpatient group. Of the outpatients' parents, 67.4% (n = 147) were fully vaccinated vs. 38.4% (n = 58) in the inpatient group. In all, 39.7% (n = 60) of the inpatients' parents were unvaccinated vs. 18.3% (n = 40) in the outpatient group. There was a significant correlation between the vaccination status and the patient groups (p < 0.001); it was determined that the COVID-19 infection would be mild in children if both parents were fully vaccinated. When both parents were fully vaccinated against COVID-19, the hospitalization rate decreased and the outpatient follow-up rate increased. CONCLUSION Having both parents fully vaccinated against COVID-19 can indirectly protect their subsequently infected children from hospitalization and the long-term effects of infection. Nonetheless, more comprehensive research on delta and non-delta variants is needed.
Collapse
Affiliation(s)
- Ömer Günes
- Department of Pediatric Infectious Diseases, Ankara City Hospital, 06800 Ankara, Turkey
| | - Belgin Gülhan
- Department of Pediatric Infectious Diseases, Ankara City Hospital, 06800 Ankara, Turkey
| | - Ahmet Yasin Guney
- Department of Pediatric Infectious Diseases, Ankara City Hospital, 06800 Ankara, Turkey
| | - Fatih Üçkardeş
- Department of Biostatistics and Medical Informatics, Faculty of Medicine, Adıyaman University, Adıyaman 02040, Turkey
| | - Seval Ozen
- Department of Pediatric Infectious Diseases, Ankara City Hospital, 06800 Ankara, Turkey
| | - Latife Guder
- Department of Pediatric Infectious Diseases, Ankara City Hospital, 06800 Ankara, Turkey
| | - Ozlem Mustafaoglu
- Department of Pediatric Infectious Diseases, Ankara City Hospital, 06800 Ankara, Turkey
| | - Pinar Bayraktar
- Department of Pediatric Infectious Diseases, Ankara City Hospital, 06800 Ankara, Turkey
| | - Aysun Yahşi
- Department of Pediatric Infectious Diseases, Ankara City Hospital, 06800 Ankara, Turkey
| | - Tuğba Erat
- Department of Pediatric Infectious Diseases, Ankara City Hospital, 06800 Ankara, Turkey
| | - Saliha Kanik-Yuksek
- Department of Pediatric Infectious Diseases, Ankara City Hospital, 06800 Ankara, Turkey
| | - Gulsum Iclal Bayhan
- Department of Pediatric Infectious Diseases, Ankara City Hospital, 06800 Ankara, Turkey
| | | |
Collapse
|